Overview
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 15, 2025 | EpilepsyGTx Secures $33M to Pioneer Single-Dose Gene Therapy for Refractory Epilepsy | EpilepsyGTx just raised $33 million. This Series A funding will fuel clinical trials. Their focus? A gene therapy for focal refractory epilepsy (FRE). FRE impacts millions globally. Current treatments often fail. EpilepsyGTx offers a potent... |
| Dec 12, 2025 | EpilepsyGTx Secures $33 Million Series A To Advance Single-Dose Gene Therapy For Focal Refractory Epilepsy | EpilepsyGTx, a biotechnology company focused on developing gene therapies for refractory epilepsy, has raised $33 million in a Series A financing to advance its lead program, EPY201, into first-in-human clinical trials. The funding will sup... |
| Dec 10, 2025 | Gene therapy for severe epilepsy moves forward with EpilepsyGTx’s €28 million funding | EpilepsyGTx, a Cambridge-based BioTech startup focused on research and development of gene therapies to treat refractory epilepsy, today announced it has raised €28 million ($33 million) in Series A financing to advance its lead programme E... |
| Sep 3, 2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share Tweet Share Share Email Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| Nov 10, 2021 | Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland | BASEL, Switzerland, Nov. 10, 2021 /PRNewswire/ -- Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Zambon Switzerland (Zambon), under which the company grants ... |
| Oct 5, 2021 | Акселераторы, о которых должны знать MedTech-стартапы | Акселераторы, о которых должны знать MedTech-стартапы |
| Oct 5, 2021 | Must-know accelerators for MedTech-startups | Must-know accelerators for MedTech-startups |
| Oct 5, 2021 | Акселераторы, о которых должны знать MedTech-стартапы | Акселераторы, о которых должны знать MedTech-стартапы |
| Jul 25, 2019 | Zambon Acquires Breath Therapeutics, For Up To €500M | Zambon, an Italian multinational pharmaceutical company, acquired Breath Therapeutics, a biopharmaceutical company developing an innovative inhalation therapy for Bronchiolitis Obliterans Syndrome (BOS), for € 140m (up to total € 500m subje... |
Reviews 0
FAQ about Zambon
When was Zambon founded?
Zambon was founded in 1906.
What has the press written about Zambon?
Parsers VC has collected 11 articles mentioning Zambon, among them “EpilepsyGTx Secures $33M to Pioneer Single-Dose Gene Therapy for Refractory Epilepsy” (Dec 15, 2025) and “EpilepsyGTx Secures $33 Million Series A To Advance Single-Dose Gene Therapy For Focal Refractory Epilepsy” (Dec 12, 2025).
Is Zambon still active?
Yes, Zambon is active; its latest activity on Parsers VC dates from Oct 7, 2026.